ORTHOCELL LIMITED — Capital/Financing Update 2018

Dec 10, 2018

==> picture [594 x 111] intentionally omitted <==

CelGro® approved in key UK public dental hospital

• Orthocell secures approval for use of CelGro® in major NHS Dental Hospital

• Expected to provide a boost to revenues and accelerate product awareness of CelGro®

• Birmingham Dental Hospital is a top-tier teaching Dental Hospital training more than 600 undergraduate and postgraduate dental students in the UK

• This represents the first step in growing Orthocell’s public hospital customer base , as part of its commercialisation strategy in Europe

Perth, Australia; 11[th] December 2018 : Regenerative medicine company Orthocell Limited (ASX:OCC, “Orthocell”, or the “Company”) is pleased to announce that CelGro® has been approved for use in Birmingham Dental Hospital (“BDH”), one of only ten public dental hospitals in England.

The approval for the use of CelGro® at BDH was driven Key Opinion Leader (“KOL”) feedback and recommendation, underpinned by clinical data demonstrating CelGro® assists clinicians in delivering superior tissue repair outcomes (up to 26% better quality newly formed bone) compared to the market leading dental product.

The approval represents a key milestone in the delivery of Orthocell’s marketing and sales strategy. In addition to generating CelGro® sales, this provides the opportunity for CelGro® to be used by leading clinicians while educating upcoming dentists. This is expected to have a substantial impact on educating and growing product awareness and Orthocell will leverage this approval to grow its UK customer base.

Orthocell Managing Director Paul Anderson said: “This achievement creates exciting and valuable opportunities for Orthocell. Not only does BDH perform thousands of dental implant procedures each year, but as a top-tier teaching institution, dental students will be exposed to the superior performance of CelGro®. This approval is an important step into the UK public sector and we look forward to expanding our customer base in Europe and accelerate CelGro® sales.”

BDH is operated by the National Health Service (“NHS”), the public health service system in England. BDH is a top-tier research institution, providing teaching opportunities for more than 600 postgraduate and undergraduate dental students.

Approximately 300,000 dental implant procedures are performed in the UK each year and approximately 20% are performed by public dental hospitals. The use of CelGro® in dental implant procedures prevents tissue in growth and enables high-quality bone repair.

Ph: +61 8 9360 2888 Fax: +61 8 9360 2899 www.orthocell.com.au

==> picture [594 x 111] intentionally omitted <==

About Birmingham Dental Hospital (BDH):

BDH is operated by the NHS and one of only ten dental hospitals in England. BDH provides a unique range of government funded dental services for the public including walk-in emergency dental care, restorative dentistry, oral surgery, oral medicine, orthodontics and paediatric dentistry.

BDH is also home to the University of Birmingham's School of Dentistry, a world-class research institution providing a modern learning environment for more than 600 postgraduate and undergraduate and postgraduate dental students. There are approximately 115,000 consultant-led dental treatments and procedures undertaken at BDH each year, along with specialised training for dental students, dental nurses, dental hygienists and therapists.

For more information, please contact:

General enquiries Investor enquiries Media enquiries Paul Anderson Joel Seah Haley Chartres Orthocell Limited Vesparum Capital Hales[2 ] Communications Managing Director P: +61 8 9360 2888 P: +61 3 8582 4800 P: +61 423 139 163 E: paulanderson@orthocell.com.au E: orthocell@vesparum.com E: haley@h-squared.com.au

About Orthocell Limited

Orthocell is a regenerative medicine company focused on regenerating mobility for patients by developing products for the repair of a variety of soft tissue injuries. Orthocell’s portfolio of products include TGA-licensed cell therapies Autologous Tenocyte Implantation (Ortho-ATI®) and Autologous Chondrocyte Implantation (Ortho-ACI®), which aim to regenerate damaged tendon and cartilage tissue. The Company’s other major product is CelGro®, a collagen medical device which facilitates tissue repair and healing in a variety of orthopaedic, reconstructive and surgical applications. Orthocell recently received European regulatory approval (CE Mark) for CelGro®. The collagen medical device can now be marketed and sold within the European Union for a range of dental bone and soft tissue regeneration procedures and is being readied for market authorisation in the US.

For more information on Orthocell, please visit www.orthocell.com.au or follow us on Twitter @Orthocellltd and Linkedin www.linkedin.com/company/orthocell-ltd =

Ph: +61 8 9360 2888 Fax: +61 8 9360 2899 www.orthocell.com.au